| Cell line name |
OV-MZ-22 |
|---|
| Accession |
CVCL_E117 |
|---|
| Resource Identification Initiative |
To cite this cell line use: OV-MZ-22 (RRID:CVCL_E117) |
|---|
| Comments |
Doubling time: 42 hours (PubMed=11733966). |
|---|
| Sequence variations |
|
|---|
| Disease |
Ovarian carcinosarcoma (NCIt: C9192)
Malignant mixed Mullerian tumor of the ovary (ORDO: Orphanet_213512) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
56Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=11242531; DOI=10.1089/10430340150504019
Ansgar Bruning, Tanja Kohler, Sven Roy Quist, Shan Wang-Gohrke, Volker J. Mobus, Rolf Kreienberg, Ingo Bernard Runnebaum;
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001) PubMed=11733966; DOI=10.1006/gyno.2001.6425
Volker J. Mobus, Claus-Dieter Gerharz, Wolfgang Weikel, Oliver Merk, Liane Dreher, Rolf Kreienberg, Roland Moll;
Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.
Gynecol. Oncol. 83:523-532(2001) PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Sven Roy Quist, Shan Wang-Gohrke, Tanja Kohler, Rolf Kreienberg, Ingo Bernard Runnebaum;
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004) |
|---|
| Cross-references |
|---|
| Cell line collections (Providers) |
ABM; T8234
|
|---|
| Encyclopedic resources |
Wikidata; Q54936847
|
|---|
| Entry history |
|---|
| Entry creation | 22-Oct-2012 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 14 |
|---|
